Sanofi's Dupilumab Injection for Moderate-to-Severe Atopic Dermatitis in Children Aged 6 to <12 Years Recommended for Priority Review in China

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) announced that the new indication marketing authorization application for dupilumab injection (dupilumab, English trade name: Dupixent) submitted by Sanofi in China has been proposed for priority review by the CDE. The proposed indication is: for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients aged 6 to less than 12 years who are inadequately controlled by or for whom topical prescription therapies are not recommended.